September 2021

Pharmalot By Ed Silverman

Pharmalittle: Run on ivermectin tablets leaves less for livestock; Pfizer Covid-19 shot for kids may not come until November

Biotech By Adam Feuerstein

Editas CRISPR treatment improved vision for one patient, but not others, early data show

Pharmalot By Ed Silverman

As lawsuits mounted, Purdue cultivated conversations with a controversial addiction policy group

First Opinion Podcast By Patrick Skerrett

Listen: Revisiting Uché Blackstock on leaving academic medicine

First Opinion By William F. Haning, III

Overdose prevention sites can save lives and promote recovery. We must be willing to try them

Health Tech By Hyacinth Empinado

Watch: The tedious process of training computers to think about medicine, explained

Pharmalot By Ed Silverman

Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited

Pharmalot By Ed Silverman

FDA tells drug makers to redo studies run by two contract research firms due to data integrity issues

Politics By Nicholas Florko

The government’s Covid-19 response will continue in a shutdown, but health agencies will face major staff shortages

Health By Andrew Joseph

Side effect rates from a third Covid-19 vaccine dose similar to those after second shot, early data indicate

Health Tech By STAT Staff

Behind Epic’s algorithm to detect sepsis before it progresses

Pharmalot By Ed Silverman

Pharmalittle: Sanofi ends work on mRNA Covid-19 vaccine; Biogen seeks fast FDA approval of another Alzheimer’s drug

Health By Nicholas St. Fleur and Usha Lee McFarling

STAT+ Conversation: How medicine’s biggest journals are confronting racism

Biotech By Kate Sheridan

Graduate students launch an entrepreneurship program to bring new faces to biotech

Biotech By Adam Feuerstein

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

First Opinion By C.K. Wang

Most Read

Biden administration favors insurers over doctors, hospitals in controversial new surprise billing regulations

Listen: Health equity ‘tourism,’ an $11B biopharma acquisition, & a bony Covid protest

Genetic information can be messy. Mapping proteins could offer a clearer view of what’s driving cancer

Key Senate committee considers a carveout for small biotech companies in drug pricing reforms

Appeals court rules FDA ‘arbitrarily and capriciously’ approved a rare disease drug

Who telehealth isn’t reaching & Apple looks past A-fib

With $11 billion Acceleron deal, new Merck CEO hopes to convince investors there is a lot more to the biopharma giant

Virtual Event: The evolving landscape for biosimilars

All Coverage

Pharmalittle: Run on ivermectin tablets leaves less for livestock; Pfizer Covid-19 shot for kids may not come until November

Editas CRISPR treatment improved vision for one patient, but not others, early data show

As lawsuits mounted, Purdue cultivated conversations with a controversial addiction policy group

Listen: Revisiting Uché Blackstock on leaving academic medicine

Overdose prevention sites can save lives and promote recovery. We must be willing to try them

Watch: The tedious process of training computers to think about medicine, explained

Lilly cuts the wholesale price on some insulin products, but impact is likely to be limited

FDA tells drug makers to redo studies run by two contract research firms due to data integrity issues

The government’s Covid-19 response will continue in a shutdown, but health agencies will face major staff shortages

Side effect rates from a third Covid-19 vaccine dose similar to those after second shot, early data indicate

Behind Epic’s algorithm to detect sepsis before it progresses

Pharmalittle: Sanofi ends work on mRNA Covid-19 vaccine; Biogen seeks fast FDA approval of another Alzheimer’s drug

STAT+ Conversation: How medicine’s biggest journals are confronting racism

Graduate students launch an entrepreneurship program to bring new faces to biotech

Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard

Paying participants isn’t the way to improve clinical trial recruitment

Subscribe to STAT for $15 per month lorem ipsum

Month: September 2021

Most Read

All Coverage

Subscribe to STAT for $15 per month lorem ipsum